Relative Bioavailability of LY3074828 Solution Formulation in Pre-Filled Syringes Compared to Lyophilized Formulation After Single Subcutaneous Administration
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Mirikizumab (Primary)
- Indications Crohn's disease; Plaque psoriasis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 15 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Nov 2017.
- 15 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Nov 2017.
- 15 Sep 2017 Status changed from recruiting to active, no longer recruiting.